PDCD1 and non-small cell lung carcinoma: In the non-small cell lung cancer monotherapy expansion cohort, outcomes varied by prior anti-PD-1 therapy response status: anti-PD-1/L1 refractory patients (m= 23, objective response rate (ORR) 0%, disease control rate (DCR) 35%, progression-free survival (PFS) 1.9 months) versus anti-PD-1/L1 responders (n = 14, ORR 7%, DCR 50%, PFS 7.3 months).